Evaluation of rhPDGF, L-PRF, and EMD as Adjuncts to Non-surgical Periodontal Therapy for Intrabony Defects: A Randomized Controlled Clinical Trial

What this Trial Is About

Researchers are evaluating the effectiveness of three biological agents—recombinant human platelet-derived growth factor (rhPDGF), Leukocyte-Platelet Rich Fibrin (L-PRF), and Enamel Matrix Derivatives (EMD)—as additional treatments alongside minimally invasive non-surgical periodontal therapy (MINST) for intrabony defects. This 12-month randomized clinical trial includes 88 patients with single infrabony defects to compare these treatments against MINST alone. The study is designed to assess clinical and radiographic improvements in periodontal condition following treatment. Participants are randomly assigned to one of four groups: MINST combined with rhPDGF, MINST plus L-PRF, MINST plus EMD, or MINST alone as a control. The treatment involves debriding the defects using fine ultrasonic tips and hand instruments under local anesthesia, preserving soft tissue stability. In the experimental groups, the defects are filled with either a collagen sponge soaked in rhPDGF, an L-PRF membrane, or EMD gel after MINST, while the control group receives MINST without additional treatment. During the study, patients undergo clinical measurements including clinical attachment level, probing depth, gingival recession, plaque score, and bleeding on probing at baseline, 6 months, and 12 months. Standardized radiographs are taken at the same intervals to assess bone defect characteristics using dental software. The primary outcomes measured at 12 months are defect bone level and clinical attachment level, while secondary outcomes include pocket probing depth, gingival recession, defect angle, and radiographic defect area. The study uses double-blind methods to ensure unbiased assessment of results.

Clinical Effectiveness of Biologic Agents as an Adjunct to Non-surgical Periodontal Therapy of Intrabony Defects